This Biotech Stock was Once a Penny Stock but is Now Making Big Moves on the Nasdaq!

This former penny stock now a full fledged Nasdaq Biotech Stock deserves your attention & here’s why.

GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™

POTENTIAL TREATMENT OF SEVERAL SOLID TUMOR CANCERS INCLUDING: NON-SMALL CELL LUNG CANCER,…

GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference

57% of patients experienced significant reduction in AML/MDS cancer cell burden Up…

GT Biopharma to Present at Raymond James Human Health Innovation Conference

BEVERLY HILLS, Calif., June 16, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT…

GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET

BEVERLY Hills, Calif., May 18, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates

BEVERLY HILLS, Calif., May 12, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S. Miller, M.D. to Consulting Chief Scientific Officer

BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update

Posted Significant FDA Clinical Trial Results for GTB-3550 TriKE™ in AML and…

GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients

BEVERLY HILLS, Calif., April 12, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…